Bringing the fundamentals into focus…
Back to Zevra Therapeutics, Inc.
How Zevra Therapeutics, Inc. stacks up
ZVRA · against 475 other Healthcare companies of similar size
Valuation
95/ 100
Near the top of its peers.
Ranked #22 of 476 · scores higher than 94% of peers
Bars: peers in each 10-point band of the valuation score55 peers with a valuation score of 90–100, including ZVRA · Click a bar to see the companies
Why valuation scores 95?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its earnings yield, EBITDA yield and free cash flow yield, which are stronger than most Healthcare peers.
- more free cash flow for the price paid: stronger than 81% of peers. Free cash flow yield: 5.4% vs peer median 0.0%
- more operating profit (EBITDA) for the company's total value: stronger than 82% of peers. EBITDA yield: 21.6% vs peer median 4.0%
- higher earnings for the price paid: stronger than 94% of peers. Earnings yield: 9.6% vs peer median 1.5%
Metric by metric
Position: dot = ZVRA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ZVRA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 464 reported | 9.1% | 0.7% | 94% | 30% | |
| EBITDA yieldHigher is better · 480 reported | 10.4% | 3.6% | 80% | 50% | |
| Free cash flow yieldHigher is better · 200 reported | 5.4% | -4.2% | 83% | 20% | |
| Book yieldHigher is better · 476 reported | 35.8% | 45.7% | 38% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ZVRA| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 22 | 7.1B CNY (≈$994M) | 95 | 54 | |
| 22 | 109.3B JPY (≈$743M) | 95 | 76 | |
| 22 | 344M USD | 95 | 54 | |
| 22 | 17.9B ZAR (≈$986M) | 95 | 62 | |
| 22 | 609M USD | 95 | 91 | |
| 31 | 7.2B CNY (≈$1.0B) | 94 | 69 | |
| 31 | 6.4B HKD (≈$821M) | 94 | 54 | |
| 31 | 114.7B JPY (≈$780M) | 94 | 72 | |
| 31 | 141.7B JPY (≈$963M) | 94 | 68 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score